Biomark Diagnostics Inc
20B
Company Profile
Business description
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company’s objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
Contact
130 - 3851 Shell Road
RichmondBCV6X 2W2
CANT: +1 604 836-6950
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2027
Employees
Stocks News & Analysis
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
stocks
Undervalued ASX share upgrades guidance
Market share gains drive earnings upgrade despite a weak US housing backdrop.
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,097.70 | 65.40 | 0.72% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,214.67 | 7.49 | 0.03% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 62,338.60 | 2,592.59 | -3.99% |
| NZX 50 Index | 13,861.93 | 11.24 | 0.08% |
| S&P 500 | 7,413.18 | 1.20 | 0.02% |
| S&P/ASX 200 | 8,933.10 | 70.90 | 0.80% |
| SSE Composite Index | 3,815.42 | 42.82 | -1.11% |